Celltrion Confirms Early Treatment Effectiveness of COVID-19 Antibody Therapy in Mild Patients

[Asia Economy Reporter Cho Hyun-ui] Celltrion has confirmed the safety and rapid viral reduction effect of the COVID-19 antibody treatment 'CT-P59' in a Phase 1 clinical trial targeting patients with mild symptoms.

Celltrion announced on the 6th, "We presented the Phase 1 clinical trial results of CT-P59 for mild patients at the 2020 Autumn Conference of the Korean Society of Infectious Diseases and the Korean Society for Antimicrobial Therapy, held online over two days starting yesterday."

This clinical trial evaluated the safety, tolerability, clinical symptom changes, and viral changes of CT-P59 in 18 early mild COVID-19 patients at three clinical trial institutions in Korea and Europe.

As a result, no specific adverse events caused by CT-P59 administration were observed, confirming its safety and tolerability. The average time to symptom recovery after drug administration was reduced by 44% compared to the placebo group.

All patients treated with CT-P59 recovered, while some in the placebo group worsened. Most participants in this trial were elderly patients, and unlike the placebo group, none of the CT-P59 treated patients progressed to severe disease. In particular, patients with initially high viral loads showed a faster decrease in the virus compared to the placebo group, confirming the early treatment effect of CT-P59.

Celltrion is currently conducting global Phase 2 and 3 clinical trials in several countries including Korea and plans to secure interim results by the end of the year. Additionally, preventive clinical trials for close contacts are underway, aiming for global approval application next year. Since September, process verification batch production has been underway to enable immediate mass supply once the treatment development is completed.

A Celltrion official stated, "Through this clinical trial result, we have confirmed the early treatment effect of the COVID-19 antibody treatment with early administration," adding, "Since Phase 1 involved a relatively small number of patients, there are limitations to conclusively accepting the results, so we will accelerate the ongoing Phase 2 clinical trial."

This content was produced with the assistance of AI translation services.